OMERS ADMINISTRATION Corp Grows Holdings in Exelixis, Inc. $EXEL

OMERS ADMINISTRATION Corp raised its stake in Exelixis, Inc. (NASDAQ:EXEL) by 27.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 88,362 shares of the biotechnology company’s stock after buying an additional 18,800 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Exelixis were worth $3,790,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. AQR Capital Management LLC lifted its holdings in shares of Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock worth $598,647,000 after acquiring an additional 4,477,029 shares during the last quarter. Invesco Ltd. increased its stake in Exelixis by 1.6% in the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock valued at $265,379,000 after acquiring an additional 94,218 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Exelixis by 0.9% in the first quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock valued at $184,391,000 after acquiring an additional 39,920 shares during the last quarter. Morgan Stanley raised its position in Exelixis by 31.0% during the fourth quarter. Morgan Stanley now owns 4,206,656 shares of the biotechnology company’s stock valued at $184,378,000 after purchasing an additional 995,949 shares in the last quarter. Finally, UBS Group AG raised its position in Exelixis by 40.2% during the fourth quarter. UBS Group AG now owns 3,722,334 shares of the biotechnology company’s stock valued at $163,150,000 after purchasing an additional 1,067,265 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Buying and Selling at Exelixis

In related news, EVP Patrick J. Haley sold 32,110 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total value of $1,599,399.10. Following the completion of the sale, the executive vice president owned 357,638 shares of the company’s stock, valued at $17,813,948.78. This trade represents a 8.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Christopher J. Senner sold 34,901 shares of Exelixis stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the completion of the sale, the chief financial officer owned 952,317 shares in the company, valued at approximately $47,615,850. This trade represents a 3.54% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 219,170 shares of company stock worth $10,620,641 over the last three months. 2.60% of the stock is owned by corporate insiders.

Exelixis Stock Up 0.8%

Shares of EXEL opened at $55.81 on Tuesday. The stock has a market capitalization of $14.03 billion, a P/E ratio of 18.54, a PEG ratio of 1.60 and a beta of 0.42. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $57.57. The firm has a fifty day simple moving average of $53.28 and a two-hundred day simple moving average of $47.31.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.75 by $0.12. The firm had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.55 earnings per share. Sell-side analysts expect that Exelixis, Inc. will post 3.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on EXEL shares. Wells Fargo & Company upped their price objective on Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a report on Monday, July 13th. Morgan Stanley upped their target price on Exelixis from $50.00 to $53.00 and gave the stock an “equal weight” rating in a research note on Thursday. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Stifel Nicolaus boosted their price objective on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a report on Wednesday, May 6th. Finally, Royal Bank Of Canada increased their target price on shares of Exelixis from $43.00 to $46.00 and gave the company a “sector perform” rating in a report on Tuesday, July 7th. Nine equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $49.00.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.